Table 3.
Organ Involvement for Nonparticipants (at Diagnosis) and Study Participants (at Diagnosis and Follow-up)
| Organ Involvement | Nonparticipants (n = 15) |
Study Participants (n = 59) |
|
|---|---|---|---|
| At Diagnosisa | At Diagnosisb | Follow-upb | |
| Intrathoracic involvement by CT imaging | 13 (87%) | 55 (98%) | 29 (51%) |
| Radiographic stage 1 | 0 | 8 (15%) | 6 (21%) |
| Radiographic stage 2 | 12 (92%) | 43 (78%) | 19 (66%) |
| Radiographic stage 3 | 1 (8%) | 4 (7%) | 4 (14%) |
| Radiographic stage 4 | 0 | 0 | 0 |
| Cardiac | 0 | 0 | 9 (16%) |
| Eyes | 1 (8%) | 3 (5%) | 3 (5%) |
| Ears/nose/throat | 0 | 0 | 1 (2%) |
| Bone/joint | 2 (13%) | 4 (7%) | 9 (15%) |
| Skin | 1 (7%) | 1 (2%) | 1 (2%) |
| Nervous System | 0 | 0 | 1 (2%) |
| Liver | 1 (7%) | 1 (2%) | 1 (2%) |
| Spleen | 0 | 3 (5%) | 3 (5%) |
| Kidney | 0 | 1 (2%) | 0 |
| Calcium | 0 | 0 | 0 |
| Extrathoracic lymph nodes | 1 (2%) | 0 | 0 |
Organ involvement was based on World Association of Sarcoidosis and Other Granulomatous Diseases criteria. None of the comparisons between nonparticipants and participants were statistically significant.
Nonparticipants had complete data at diagnosis with the following exceptions: skin (n = 14); eye (n = 13); spleen (n = 7); bone/joint (n = 9); cardiac (n = 12); nervous system (n = 5); and extrathoracic lymph nodes (n = 3).
In the study cohort with follow-up, all cases had complete data at diagnosis and follow-up with the following exceptions: chest CT scan at diagnosis (n = 56), at follow-up (n = 57) and at both (n = 53); eye at follow-up (n = 58); spleen at follow-up (n = 57); cardiac at follow-up (n = 57); and ear/nose/throat at follow-up (n = 57).